Breakthrough Properties’ Post

🔥 Join us for the 3rd H7 Angel Club meeting in 2024, happening on July 2nd at 3pm PST via Zoom！  🚩 Featured Company: A next-generation Non-degrading #MolecularGlue platform with significant competitive advantages. Founded by a pioneer who co-established the molecular glue field 33 years ago, the company recently secured a $28M #oversubscribed Series A+ round led by 3E Bioventures, Proxima Ventures, and Lapam Capital. 📣 H7 investment team has thoroughly reviewed the project and prepared a 📝[One-Pager Investment Teaser] along with a comprehensive ✍️ [Investment Report exceeding 30 pages]. Upon signing and NDA, we are delighted to provide access to the full report.  ----------- The meeting is exclusively for investor members of H7 Angel Club, which is entirely free for qualified investors. Apply for membership to attend. Upon approval, you’ll receive further details. 🎯Investor Membership Application: https://shorturl.at/losSW 🎯Founders Submitting Their Deck: https://shorturl.at/d3UBO #angel #investmentopportunity #vc #healthcare #lifesciences #medtech #medicaldevices #biotech #biopharma #investors #familyoffice #syndicate #fundraising #clinical

🔥 Join us for the 3rd H7 Angel Club meeting in 2024, happening on July 2nd at 3pm PST via Zoom！  🚩 Featured Company: A next-generation Non-degrading #MolecularGlue platform with significant competitive advantages. Founded by a pioneer who co-established the molecular glue field 33 years ago, the company recently secured a $28M #oversubscribed Series A+ round led by 3E Bioventures, Proxima Ventures, and Lapam Capital. 📣 H7 investment team has thoroughly reviewed the project and prepared a 📝[One-Pager Investment Teaser] along with a comprehensive ✍️ [Investment Report exceeding 30 pages]. Upon signing and NDA, we are delighted to provide access to the full report.  ----------- The meeting is exclusively for investor members of H7 Angel Club, which is entirely free for qualified investors. Apply for membership to attend. Upon approval, you’ll receive further details. 🎯Investor Membership Application: https://shorturl.at/losSW 🎯Founders Submitting Their Deck: https://shorturl.at/d3UBO #angel #investmentopportunity #vc #healthcare #lifesciences #medtech #medicaldevices #biotech #biopharma #investors #familyoffice #syndicate #fundraising #clinical

𝗔𝗥𝗖𝗛, 𝗼𝗻𝗲 𝗼𝗳 𝗹𝗶𝗳𝗲 𝘀𝗰𝗶𝗲𝗻𝗰𝗲𝘀' 𝗽𝗿𝗲𝗺𝗶𝗲𝗿 𝗶𝗻𝘃𝗲𝘀𝘁𝗼𝗿𝘀, 𝗲𝘆𝗲𝘀 $𝟯𝗕 𝗳𝗼𝗿 𝟭𝟯𝘁𝗵 𝗳𝘂𝗻𝗱 ARCH Venture Partners plans to raise $3 Billion for its 13th fund, per a new SEC filing from this week. The Chicago-based venture capital firm has been one of the most high-profile backers of life sciences companies for the past few decades and is behind many big names like Illumina, Altos Labs and Vir Biotechnology, Inc., among dozens of others. The firm was the fourth most active investor in private financings last year, per a recent report from investment bank William Blair, having taken part in 18 rounds in 2023. OrbiMed, which unveiled $4.3 Billion across three new funds last fall, took first with 24 rounds. Flagship Pioneering, the investor and biotech creator behind the likes of Moderna, is also seeking $3 Billion for its next fund, per an SEC filing last November. https://lnkd.in/de5EZXwh

📈 #BiotechInnovation #StartupSuccess #ForesiteCapital 💻 Learn about Foresite Capital's recent launch of Biotech Fund VI on their blog post! This exciting development showcases a promising future for early-stage biopharma companies, with a 33% increase in median pre-money valuations indicating strong market growth. 🔬 Focusing on supporting early-stage biopharma ventures, Foresite Capital’s strategic investment in Biotech Fund VI highlights their dedication to advancing innovative solutions in the healthcare sector. This move signifies a positive outlook for startups seeking crucial financial backing and growth opportunities. 👩🏽💻 Platforms like NextRound.ai play a vital role in assisting founders with fundraising endeavors. By leveraging NextRound.ai's resources and expertise, founders can optimize their fundraising strategies, connect with potential investors, and navigate the funding landscape with ease. Visit the NextRound.ai blog for more insights! #NextRoundSupportsFounders 📍 For more details on this exciting announcement and to explore additional resources on fundraising strategies, visit the NextRound.ai blog at https://nextround.ai/blog/ 📎💰 #StartupResources #SuccessfulFundraising #EmpoweringFounders 🌤️☝🏽

It is all about giving back to the community. Do you know that scientists like to invest in other scientists? Because they understand each other. They also see through those who don't have anything of substance. After the recent acquisition of RayzeBio, co-founder Aaron Kantoff turned around and is putting the capital back into the science community that made this opportunity bloom. Are you investing back? #vcfunding #biotechinnovation #sandiego https://lnkd.in/gyjrAuW4

Today marks a pivotal moment in the journey of Caixa Capital Risc as we are unveiling our latest endeavor: Say hello to our two new evergreen funds - Criteria Venture Tech and Criteria Bio Ventures! 🌟 These funds are a testament to our innovative spirit and our commitment to forward-thinking innovation in the realms of tech and biotech. 🌐 By following us, you'll stay updated on cutting-edge developments and breakthroughs in these dynamic sectors. Our goal is to keep you informed about the latest news, investment thesis, remarkable portfolio milestones, and the ins and outs of our VC. 📈 💼 #CriteriaVentureTech #CriteriaBioVentures #investment #innovation #tech #Biotech #LifeScience

More smart money coming to therapeutics and enabling technologies... Interesting to read about JPM's expanding life science team. Despite the capital raised, you see an echoing sentiment about capital efficiency and not overpaying for assets, which is critical to keep the "virtuous VC cycle" going. https://lnkd.in/dk5xe7FU Founders and investors need to work together at the earliest stages to create a logical funding and valuation plan. this is critical so companies can grow appropriately, build value, and, ultimately, exit successfully, providing a windfall to the founder and investor that took the earliest risk, who can ultimately return capital to LPs. Get this wrong and VC's don't return money to LPs and in turn, don't raise subsequent funds. That means less money to fund new and emerging startups. We've seen early company valuations drop from pandemic-fueled highs, but there's still often a valuation mismatch between founder and investor expectations, particularly for early companies (which, admittedly, can be hard to value). This in turn, is the importance of working with smart money, truly partnering with your investors, and working hand-in-hand. #entrepreneur #investing #pharma

2023 was a year of notable milestones for the Novo Holdings Seed Investments team. Our portfolio companies raised >$460m and we launched SeedLab, a wet laboratory in Denmark which will serve to incubate scientific concepts and ideas. The Novo Holdings Seed Investments team is focused on building and investing in early-stage breakthrough life science companies and on collaborating with innovators globally. You can read the Seed Investments team’s annual review here: #lifescienceinvestments #venturecapital #venturecreation #biotech

💼🚀 Explore the Dynamics of Biotech Financing! Join us for the 'Venture & Private Equity Roundtable' at the #Sachs_BEF on September 25th, 2024, at the Mövenpick Hotel Basel. Dive into the world of venture capital and private equity that fuels the biotech industry’s growth and innovation. Co-Chaired by: Marianne Uteng, Managing Director, Novartis Venture Fund Steven Dickman, CEO, CBT Advisors Panellists: Cindy Daniel, Head of Unit - Life Sciences & Healthcare - Equity Investments, European Investment Fund (EIF) Hubert Birner, Managing Partner, TVM Capital Life Science Magne Stoknes, Principal, Novo Holdings A/S Matthieu Coutet, Partner, Sofinnova Partners Nigel Sheail, Venture Partner, Versant Ventures This roundtable will feature an in-depth discussion with leading venture capitalists and private equity investors who are shaping the future of biotech. Gain insights into investment trends, strategies for navigating the funding landscape, and perspectives on upcoming market opportunities in the biotech sector. Don't miss this chance to connect with industry leaders and financial experts. Secure your spot today at www.sachsforum.com/24bef and be part of this enlightening discussion, both #InPerson & #Online, during the Sachs Autumn Life Sciences Week. #BiotechVC #PrivateEquity #BiotechFunding #InvestmentTrends #LifeSciences #VentureCapital #Biotech #SALSW

Hippocrates Opportunities Fund, a new venture firm founded by investment banker William J. Kridel Jr. and physician Mitchell Ng, is seeking up to $30 million to invest in privately held and publicly traded life sciences companies. Key takeaways: The launch of Hippocrates Opportunities Fund reflects the growing interest and focus on investments in the life sciences industry. Ferghana Partners, founded by Kridel in 1991, has a strong track record of working with life sciences companies and will continue to play a role in the fund's investments. Kridel's extensive experience and interactions with over 1,500 life sciences companies makes him a valuable asset to the new venture firm. Counter arguments: The size of the fund, $30 million, may be considered relatively small in comparison to other venture capital funds. The fund's specific focus on the life sciences industry may limit its potential for diversification and returns. #venturecapital #lifesciences #tech https://lnkd.in/gVaywm7E